Kenvue Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KVUE research report →
Range $19 – $20
Price Chart
About the company
Kenvue Inc. functions as a global leader in the consumer health sector. The company structures its operations across three primary divisions: Self Care, Skin Health and Beauty, and Essential Health.
- CEO
- Kirk L. Perry
- IPO
- 2023
- Employees
- 21,890
- HQ
- Summit, NJ, US
AI snapshot
Six angles, distilled from the data.
The stock is in a constructive medium-term uptrend, trading above both the 50-day and 200-day moving averages. It sits closer to its 52-week high than its low, with a low-beta defensive profile that has held up better than the broader market.
Street sentiment is cautious-to-neutral, with a Hold consensus and an average target of $19.50, only modestly above the last close. Recent actions are mostly reiterations and target nudges, while Jefferies cut to Hold earlier this year, reinforcing a wait-and-see stance.
Execution has been solid, with 6 of the last 8 quarters beating EPS estimates, though the latest quarter missed by 3.1%. Next-year EPS estimates point to $1.2359 versus a $0.85 TTM base, so shareholders should watch whether margin discipline keeps the beat streak intact.
No notable discretionary insider buying or selling stands out; the only clear sale was a 3,700-share disposition by the CFO & CAO for $66,988.50. Most other activity was award, exempt, or in-kind related, which reads as compensation flow rather than a conviction signal.
Profitability is healthy for a consumer staples name, with a 58.4% gross margin, 19.42% operating margin, and 10.76% net margin. Growth is steady rather than fast, with revenue up 3.0% year over year and earnings up 8.5%, while free cash flow reached $2.672 billion.
KVUE’s defensive consumer-health mix and 0.431 beta make it steadier than many branded consumer peers, but the market is not paying a premium for growth. At 16.27x earnings, it trades near a modest consumer staples multiple rather than a high-expectation valuation.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.49B
- P/E
- 21.84
- Fwd P/E
- 16.21
- PEG
- 1.24
- P/S
- 2.37
- P/B
- 3.46
- EV/EBITDA
- 13.85
- Div Yield
- 4.38%
- Gross Margin
- 58.19%
- Op Margin
- 19.52%
- Net Margin
- 10.76%
- ROE
- 15.58%
- ROIC
- 10.07%
Latest fiscal year · YoY change
- Revenue
- $15.12B-2.1%
- Gross Profit
- $8.79B-1.9%
- Op Income
- $2.70B
- Net Income
- $1.47B+42.7%
- EPS
- $0.77+42.6%
- OCF Growth
- +24.2%
- FCF Growth
- +29.0%
- 52W High
- $21.78
- 52W Low
- $14.02
- 50D MA
- $18.98
- 200D MA
- $17.79
- Beta
- 0.43
- RSI (14)
- 49
- Avg Volume
- 20.88M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Kenvue posted a weak second quarter and cut 2025 guidance, while management signaled an aggressive turnaround, tighter focus, and an active strategic review of alternatives.· August 7, 2025
- Organic sales fell 4.2%; adjusted operating margin was 22.7%, adjusted EPS was $0.29 versus $0.32 a year ago, and adjusted gross margin was 60.9%.
- Global consumption outpaced organic sales across all segments, but management said execution, inventory timing, and soft seasonal demand weighed on the quarter.
- The Board is pursuing a comprehensive review of strategic alternatives, including possible portfolio optimization, while the company also pushes immediate operating changes.
- Management highlighted self-induced complexity: 115 brands, but 41 drive over 3/4 of sales; the long tail of SKUs contributes about 1% of sales.
- Full-year 2025 guidance was cut to low-single-digit organic sales decline, adjusted operating margin down versus last year, and adjusted EPS of $1.00 to $1.05.
- Tariffs are now expected to carry about a $150 million annualized gross impact, though below that in 2025 due to timing.
Second-quarter organic sales declined 4.2%. Adjusted gross margin contracted 70 basis points to 60.9%, adjusted operating margin contracted 10 basis points to 22.7%, and adjusted diluted EPS was $0.29 versus $0.32 a year ago. Adjusted net income was $560 million, and below-the-line items were unfavorable year over year, with net interest expense up about $2 million to $94 million and the adjusted tax rate at 26.9% versus 25.7%. For 2025, Kenvue now expects organic sales down low single digits, about neutral currency impact, adjusted operating margin to contract versus last year, tariff impact of about $150 million annualized gross and below that in 2025, and adjusted diluted EPS of $1.00 to $1.05 including a low-single-digit currency drag.
Kirk Perry framed the quarter as below expectations and said the company must move with urgency, simplify the portfolio, and sharpen execution. He emphasized consumer-centric brand building, better e-commerce execution, fewer and bigger innovation bets, and a more choiceful allocation of resources to the biggest brands, markets, and initiatives. His tone was urgent but confident, repeatedly saying the issues are fixable and that the team has turned around similar businesses before.
Amit Banati said the company has healthy gross margins but sees room to expand margins over time through supply chain productivity, procurement, network optimization, planning, and digitization. He also pointed to SG&A above peer benchmarks because of separation-related costs, plus opportunities to improve working capital and cash conversion. On the quarter, he cited the 4.2% organic sales decline, 60.9% gross margin, 22.7% adjusted operating margin, and $0.29 adjusted EPS, and said Q2 weakness came from softer categories, seasonal and inventory issues, U.S. pricing actions, and FX.
Analysts focused on the timing and scope of the turnaround, especially how much of the complexity could be reduced quickly versus through strategic portfolio changes. Management said the Board review is broad and ongoing, but it is too early to specify restructuring actions or cash costs; the near-term focus is on removing obvious SKU complexity, improving e-commerce, and concentrating on the biggest brands and markets. Questions also probed the outlook for the back half, and Amit said July trends still look similar to Q2, with consumption ahead of organic sales but seasons remaining weak, while Q4 should benefit from easier comparisons to last year’s trade accruals and China weakness.
Management pointed to clear pockets of strength: Tylenol has 12 consecutive quarters of U.S. share improvement, Nicorette has 7 consecutive quarters of share gains, and Neutrogena Face and OGX showed sequential or positive consumption improvement. They also said EMEA and Latin America were encouraging, global consumption in Skin Health and Beauty stabilized for the first time in more than a year, and the back half includes the most robust innovation pipeline in years. The Board’s strategic review could unlock portfolio or structural value if it leads to sharper focus.
The quarter showed a large gap between consumption and reported sales, and management said execution and share are not where they need to be. Category softness, weak allergy and sun seasons, retailer inventory swings, China timing issues, and price investments all pressured results, while July trends still looked similar to Q2. Management also acknowledged complexity, underdeveloped e-commerce, tougher conditions in North America and APAC, and margin pressure from tariffs, inflation, and strategic reinvestment.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.9%
- Shares Outstanding
- 1.92B
- Float Shares
- 1.92B
of shares held by institutions
1,047 13F filers
Buy/sell ratio 3.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for KVUE, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kevin HernHouse · OK01 | Sell | Aug 5, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Jun 16, 26 | Filing → |
| Kevin HernHouse · OK01 | Sell | Mar 17, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Feb 10, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Jan 9, 26 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 23, 24 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Oct 1, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 12, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Oct 7, 25 | Filing → |
| Lisa McClainHouse · MI09 | Buy | Sep 25, 25 | Filing → |
| Valerie HoyleHouse · OR04 | Sell | Sep 23, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Valerie HoyleHouse · OR04 | Buy | Oct 29, 24 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 26, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 234.95M | ▲ 1.60M |
| Fmr LLC | 157.05M | ▲ 21.96M |
| Blackrock, Inc. | 150.83M | ▲ 5.53M |
| Vanguard Capital Management LLC | 125.31M | ▲ 890.53K |
| State Street Corp | 121.62M | ▲ 2.05M |
| Geode Capital Management, LLC | 52.02M | ▲ 751.10K |
| Pentwater Capital Management LP | 51.13M | ▼ 870.00K |
| Independent Franchise Partners Llp | 50.43M | ▲ 1.22M |
| Norges Bank | 46.16M | ▲ 46.16M |
| Massachusetts Financial Services Co | 44.72M | ▼ 5.03M |
| Millennium Management LLC | 36.94M | ▲ 5.14M |
| Hbk Investments L P | 28.00M | ▲ 7.00M |
Held by 1,426 ETFs
Biggest fund positions in KVUE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 31, 26 | Dasgupta Anindya | other | 16,418.87 |
| Jul 31, 26 | Dasgupta Anindya | other | 16,418.87 |
| Jun 29, 26 | Smith Jeffrey C | other | 1,413 |
| Jun 29, 26 | ALLISON RICHARD E JR | other | 1,413 |
| Jun 10, 26 | Howlett Heather | sell | 3,700 |
| May 21, 26 | Smith Jeffrey C | other | 10,309 |
| May 21, 26 | Hofstetter Sarah | other | 10,309 |
| May 21, 26 | HOLDEN BETSY D | other | 10,309 |
| May 21, 26 | MERLO LARRY J | other | 16,036 |
| May 21, 26 | PRABHU VASANT M | other | 10,309 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our KVUE coverage
Recent articles, reports, and earnings notes.

Kenvue (KVUE): Turnaround Signs, But Patience Needed
Kenvue is showing early stabilization with improving margins and revenue growth, but debt, mixed segment performance, and a pending Kimberly-Clark combination keep the stock in Hold territory.

Kenvue Inc. (KVUE) slips as earnings analysis digs deeper
Kenvue Inc. (KVUE) slips after an earnings miss, but the real story is in the deeper analysis. This breakdown examines what drove the results, how management’s outlook compares with expectations, and what the numbers may signal for the stock ahead.

Kenvue Inc. (KVUE) slips as earnings misses weigh on shares
Kenvue Inc. (KVUE) slips 2.4% after reporting earnings misses, with investors reacting to weaker-than-expected results and pressure on the consumer health maker's outlook.
Want a deeper read on KVUE?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
32,710 Shares in Kenvue Inc. $KVUE Purchased by AssuredPartners Investment Advisors LLC
defenseworld.net · Aug 20
B & T Capital Management DBA Alpha Capital Management Makes New Investment in Kenvue Inc. $KVUE
defenseworld.net · Aug 18
Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel
prnewswire.com · Aug 13
Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects
zacks.com · Aug 12
Kimberly-Clark: Temporary Headwinds, Strong Innovation And Kenvue Synergies Support A Buy
seekingalpha.com · Aug 12
Kimberly-Clark: 'Buy' This Undervalued Dividend King Before Kenvue Closes
seekingalpha.com · Aug 7
How Reddit and Wall Street See Kenvue as Buyout Nears
247wallst.com · Aug 7
Kenvue Stock Falls 2.7% as Growth Arrives With Thinner Margins
gurufocus.com · Aug 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed August 16, 2026 · Live quote · Not investment advice